MIT Technology Review: A Pancreas in a Capsule
The MIT Technology Review published a piece expressing optimism about our “cells in a sack” approach to treating type 1 diabetes. ViaCyte is mentioned as only the third company in the United States to...
View ArticleViaCyte Licenses Cell Differentiation Technology to Takara Bio Inc.
SAN DIEGO, November 16, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in...
View ArticleViaCyte to Present at IDF World Diabetes Congress 2015
SAN DIEGO, November 17, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in...
View ArticleDiabetes Forecast: 12 Products in the Diabetes Pipeline
Diabetes Forecast highlighted ViaCyte’s first-of-a-kind islet cell replacement therapy in an article discussing twelve innovative products being developed to treat and manage type 1 diabetes. ViaCyte...
View ArticleFilmmaker Documents ViaCyte’s Quest to Find a Better Treatment for Type 1...
Lisa Hepner, a filmmaker living with type 1 diabetes, and her husband Guy Mossman are producing a feature-length documentary on ViaCyte’s efforts to develop a better treatment for diabetes. The...
View ArticleViaCyte Reports Positive Preliminary Results
ViaCyte reported positive preliminary results from the Company’s Phase 1/2 clinical trial of PEC-EnCap (also known as VC-01) product candidate. The company is the first to advance an encapsulated...
View ArticleViaCyte Acquires Rights to BetaLogics Assets
For more than a decade, ViaCyte and BetaLogics have been independently working toward a stem cell-derived therapy for diabetes. In February of 2016, ViaCyte and Janssen Biotech, Inc., one of the...
View ArticleViaCyte Featured in PharmaVOICE’s Innovator’s Corner
PharmaVOICE talked with Dr. Paul Laikind, ViaCyte’s President and CEO, about how the company is developing a unique stem cell-derived therapy for type 1 diabetes. Type 1 diabetes affects an estimated...
View Article2016 San Diego JDRF Annual “ONE Walk”
Team ViaCyte Participates in Ninth JDRF "ONE Walk" 2016 marks the ninth year Team ViaCyte has participated in the JDRF One Walk by fundraising and walking in the San Diego event. The walk will take...
View Article
